May 9, 2025

The Weekly Recap 5/9/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

The Weekly Recap 5/9/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

Weekly Recap 16_9 - 05.09.2025

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $45M in new funds, receive regulatory clearance, announce product launches, and much more on the road to LSI Asia ‘25 in Singapore (June 10-13).

AliveCor

Launched the KardiaMobile® 6L Max, an AI-powered personal ECG system with the widest range of arrhythmia detection available over the counter. The company also introduced KardiaAlert, a new feature for KardiaCare subscribers that monitors ECG changes over time and alerts patients to potential risks, empowering earlier interventions and more informed care conversations.

Avvio Medical

Treated the first patients in its clinical trial of the Enhanced Lithotripsy System (ELS), a minimally invasive kidney stone therapy designed for outpatient settings. With IDE approval from the FDA, Avvio aims to shift treatment out of the OR and into ASCs and cystoscopy suites, eliminating the need for general anesthesia, fluoroscopy, or expensive capital equipment.

Cerulean Scientific

Shared results from Aim 1 of its NIH Phase 1 grant with strong preclinical results showing that TLP-coated vascular grafts resisted thrombus formation over 90 days of flow-conditioning. The tethered liquid perfluorocarbon coating maintained its omniphobic properties under physiologic shear, marking a key milestone in redefining care standards for peripheral artery disease.

Cosm Medical

Closed the first tranche of its Seed Extension round to accelerate commercialization of its AI-powered, personalized, 3D-printed pelvic health solutions. The funding supports expansion following FDA clearance and fuels upcoming clinical presentations at IUGA and key events across the U.S. women’s health landscape.

Coramaze Technologies

Appointed medtech industry veteran Rob ten Hoedt as Chair of the Board to guide the global strategy and clinical advancement of its Tripair™ system for tricuspid regurgitation. The appointment, following a successful executive search by Coulter Partners and MTIP, marks a pivotal step as Coramaze transitions from feasibility studies toward pivotal trials and commercialization.

Endospan

Reported positive 30-day results from the TRIOMPHE IDE clinical study of the NEXUS® Aortic Arch Stent-Graft System, with 0% operative mortality and no Type Ia, Type Ib, or Type III endoleaks. The data, presented at AATS 2025, support NEXUS as a promising alternative to open surgery for high-risk patients with complex aortic arch pathologies.

Field Orthopaedics

Received TGA ARTG inclusion for the Extremity All Suture System (EASS) Griplasty™ Systems, a single-incision, all-suture implant developed to treat advanced-stage thumb carpometacarpal osteoarthritis. The regulatory milestone supports broader access to innovative surgical options for treating one of the most common degenerative conditions of the hand.

GLEAMER

Secured CE mark for BoneCT, the company’s first CT application and the launchpad for its OncoView oncology imaging suite. BoneCT uses slice-by-slice AI detection and picture archiving and communication system (PACS) integration to help radiologists identify small, often-missed bone metastases, supporting earlier diagnosis and treatment.

INBRAIN Neuroelectronics

Was awarded a €4 million grant from Spain’s PERTE Chip initiative to accelerate development of its graphene-based brain-computer interfaces. The funding supports INBRAIN’s mission to deliver ultra-precise neuromodulation therapies for neurological diseases while advancing Spain’s leadership in deep tech innovation.

QV Bioelectronics

Was awarded £1.2 million from Innovate UK’s Biomedical Catalyst to advance GRACE, the company’s implantable therapy for brain tumor patients. The funding will support critical preclinical activities as QV moves closer to initiating its first-in-human trial for this novel treatment approach.

Sidekick Health

Secured €35M in venture debt from the European Investment Bank (EIB) to accelerate R&D, expand AI-powered digital therapeutics, and strengthen its global platform infrastructure. The financing, backed by the InvestEU initiative and complemented by a €7M capital injection, positions Sidekick to scale its commercial impact across chronic and specialty care.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.